Publications

All Publications

▪     Bolomsky A*, Choi J*, Phelan JD. Genotype from Phenotype: Using CRISPR Screens to Dissect Lymphoma Biology. Methods in Molecular Biology (2025):2865:241-257.  doi: 10.1007/978-1-0716-4188-0_10. (Co-first author, *equal contributions)

▪     Bolomsky A, Ceribelli M, Scheich S, Rinaldi K, Huang DW, Chakraborty P, Pham L, Wright GW, Hsiao T, Morris V, Choi J, Phelan JD, Holewinski RJ, Andresson T, Wisniewski J, Riley D, Pittaluga S, Hill E, Thomas CJ, Muppidi J, Young RM. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer Cell (2024) Jul 8;42(7):1185-1201.e14.doi:10.1016/j.ccell.2024.05.026. (Co-author)

▪     Choi J, Ceribelli M, Phelan JD, Haupl B, Huang DW, Wright GW, Hsiao T, Morris V, Ciaccarese F, Wang B, Corcoran S, Scheich S, Yu X, Xu W, Yang Y, Zhao H, Zhou J, Zhang G, Muppidi J, Inghirami GG, Oellerich T, Wilson WH, Thomas CJ, Staudt LM. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer Cell (2024) May 2:S1535-6108(24)00131-4. doi: 10.1016/j.ccell.2024.04.007 (First author)

▪     Corcoran SR, Phelan JD, Choi J, Shevchenko G, Fenner RE, Yu X, Scheich S, Hsiao T, Morris VM, Papachristou EK, Kishore K, D’santos CS, Ji Y, Pittaluga S, Wright GW, Urlaub H, Pan KT, Oellerich T, Muppidi J, Hodson DJ, Staudt LM. Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma. Cancer Discovery (2024) Apr 25. doi: 10.1158/2159-8290.CD-23-0802 (Co-author)

▪     Phelan JD*, Scheich S*, Choi J, Wright GW, Häupl B, Young RM, Rieke SA, Pape M, Ji Y, Urlaub H, Bolomsky A, Doebele C, Zindel A, Wotapek  T, Kasbekar M, Huang DW, Coulibaly ZA, Morris VM, Zhuang X, Enssle JC, Yu X, Xu W, Yang Y, Zhao H, Wang Z, Tran AD, Shoemaker CJ, Shevchenko G, Hodson DJ, Shaffer AL, Staudt LM, and Oellerich T. Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer Cell (2024) Jan 11, DOI: https://doi.org/10.1016/j.ccell.2023.12.01 (Second Author)

▪     Zhou N, Choi J, Grothusen G, Kim BJ, Ren D, Cao Z, Liu Y, Li Q, Inamdar A, Beer T, Tang TY, Perkey E, Maillard I, Bonasio R, Shi J, Ruella M, Wan L, Busino L. DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemo-resistance. Blood, (2023) 142 (11): 973–988. (Second author)

▪     Scheich S, Chen J, Liu J, Schnutgen F, Enssle JC, Ceribelli M, Thomas CJ, Choi J, Morris V, Hsiao T, Nguyen H, Wang B, Bolomsky A, Phelan JD, Corcoran S, Urlaub H, Young RM, Haupl B, Wright GW, Huang DW, Ji Y, Yu X, Xu W, Yang Y, Zhao H, Muppidi J, Pan KT, Oellerich T, Staudt LM.  Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer Discovery, (2023) May4; CD-22-1401.  doi: 10.1158/2159-8290.CD-22-1401 (Co-author)

▪     Shaffer A, Phelan JD, Wang JQ, Huang D, Wright GW, Kasbekar M, Choi J, Young RM, Webster DE, Yang Y, Zhao H, Yu X, Xu W, Roulland S, Ceribelli M, Zhang X, Wilson KM, Chen L, McKnight C, Klumpp-Thomas C, Thomas CJ, Häupl B, Oellerich T, Rae Z, Kelly MC, Ahn IE, Syn C, Gaglione EM, Wilson WH, Wiestner A, Staudt LM. Overcoming acquired resistance to BTK inhibitors. Blood Cancer Discovery, (2021) 2 (6): 630–647. https://doi.org/10.1158/2643-3230.BCD-21-0063 (Co-author)

▪     Yoshida A*, Choi J*, Jin H, Li Y, Bajpai S, Diehl JA. Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3. Oncogene, 2020 Oct 29. doi: 10.1038/s41388-020-01532-4. (Co-First Author, *equal contributions)

▪     Choi J, Phelan JD, Shaffer AL 3rd, Young RM, Wang Z, Huang DW, Zhao H, Wright GW, Oellerich T, Staudt LM. Regulation of B cell receptor-dependent NF-kB signaling by the tumor suppressor KLHL14. PNAS, 2020 March 3, https://doi.org/10.1073/pnas.1921187117. (First Author)

▪     Choi J, Busino L. E3 ubiquitin ligases in B-cell malignancies. Cell Immunology, 2019 Jun; 340:103905. doi: 10.1016/j.cellimm.2019.02.004. (First Author)

▪     Choi J*, Zhou N*, Busino L. KLHL6 is a tumor suppressor gene in diffuse large B-cell lymphoma. Cell Cycle, 2019 Feb;18(3):249-256. doi: 10.1080/15384101.2019.1568765. (Co-First Author, *equal contributions)

▪     Choi J, Saraf A, Florens L, Washburn MP, and Busino L. PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. Cell Cycle, 2018 Sep 13. doi: 10.1080/15384101.2018.1522912. (First Author)

▪     Choi J, Lee K, Ingvarsdottir K, Bonasio R, Saraf A, Florens L, Washburn MP, Tadros S, Green MR, Busino L. Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor Roquin2. Nat Cell Biol, 2018 May 20(5):586-596. doi: 10.1038/s41556-018-0084-5. (First Author, Spotlighted by “Research Watch” review in Cancer Discovery)

▪     Dews M, Tan GS, Hultine S, Raman P, Choi J, Duperret EK, Lawler J, Bass A, Thomas-Tikhonenko A. Masking epistasis between MYC and TGF-b pathways in antiangiogenesis-mediated colon cancer suppression. J Natl Cancer Inst, 2014 Apr;106(4):dju043. doi: 10.1093/jnci/dju043. (Co-Author)